The Effect of Ocufolin® forte in patients with neovascular age-related macular degeneration

New Publication by Prof. T. Josifova

In March 2025, Prof T. Josifova published a pilot study with 27 patients suffering from neovascular AMD in ‘Advances in Ophthalmology Practice and Research’. The pilot study investigated whether the intake of a specific micronutrient combination in addition to anti-VEGF therapy influences the course of the disease.

The patients, who were already receiving anti-VEGF therapy before the start of the study, were divided into an Ocufolin group (15 patients) and a control group (12 patients). Both groups were treated monthly with anti-VEGF injections during the study. The Ocufolin group additionally took 1 capsule of Ocufolin® forte daily for the duration of the study of 4 months.

The results of this study showed that the increased homocysteine blood level in the Ocufolin group and the increased retinal venous pressure in the Ocufolin group were significantly reduced. A notable finding was that 66% in the Ocufolin group and 41% in the control group had no retinal fluid at the end of the study. By lowering homocysteine blood levels and retinal venous pressure, an altered B-vitamin metabolism can be corrected and retinal microcirculation improved.

Ocufolin® forte can also effectively support the standard therapy of nAMD. The study summary with the graphical representation of the study results and the original publication can be found here.